Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06326996 · ClinicalTrials.gov registry record · Early Phase 1

Thiamine Intervention and Coronary Artery Bypass Grafting

A Early Phase 1 study of Coronary Heart Disease and Coronary Artery Bypass Grafting, sponsored by University of California, Los Angeles.

Recruiting
Registry status
Early Phase 1
Development phase
52
Enrollment target
1
Study location

NCT06326996 is a Early Phase 1 study of Coronary Heart Disease and Coronary Artery Bypass Grafting that is actively recruiting participants, run by University of California, Los Angeles. The registered enrollment target is 52 participants, below the 1,485-participant average among 19 other Coronary Heart Disease trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06326996, a Early Phase 1 study of Coronary Heart Disease and Coronary Artery Bypass Grafting, is actively recruiting participants, sponsored by University of California, Los Angeles.

RECRUITING
Registry status
Early Phase 1
Development phase
52 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to gain a better understanding of the association between brain changes and cognitive deficits in coronary heart disease (CHD) patients undergoing coronary artery bypass grafting (CABG) and whether a low-cost thiamine intervention can be used to reduce post-CABG cognitive issues in CHD subjects.

Interventions

  • DRUG Placebo
  • DRUG Thiamine

Study Locations (1)

California

  • UCLA - Los Angeles

Trial Details

FieldValue
Enrollment Target 52 participants
Start Date 2024-10-10
Est. Completion 2026-09-30
Phase Early Phase 1

What the Registry Record Tells You About NCT06326996

The ClinicalTrials.gov registry entry for NCT06326996 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,485-participant average among 19 other Coronary Heart Disease trials with a reported enrollment target (96% lower). The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Coronary Heart Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06326996 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT06326996 about?

NCT06326996 is a clinical study titled "Thiamine Intervention and Coronary Artery Bypass Grafting". The purpose of this study is to gain a better understanding of the association between brain changes and cognitive deficits in coronary heart disease (CHD) patients undergoing coronary artery bypass grafting (CABG) and whether a low-cost thiamine intervention can be used to reduce post-CABG cognitiv...

What is the current status of trial NCT06326996?

This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 52 participants. The study started on 2024-10-10. Estimated completion is 2026-09-30.

What conditions does trial NCT06326996 study?

This clinical trial studies the following conditions: Coronary Heart Disease, Coronary Artery Bypass Grafting.

What interventions are being tested in trial NCT06326996?

The interventions under investigation include: Placebo (DRUG), Thiamine (DRUG).

Who is sponsoring clinical trial NCT06326996?

This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06326996 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Coronary Heart Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.